Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
neuroscience
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial
Biological Psychiatry, Volume 54, No. 4, Year 2003
Notification
URL copied to clipboard!
Description
Background: Enhanced ability to reliably identify risk factors for suicidal behavior permits more focused decisions concerning treatment interventions and support services, with potential reduction in lives lost to suicide. Methods: This study followed 980 patients at high risk for suicide in a multicenter prospective study for 2 years after randomization to clozapine or olanzapine. A priori predictors related to diagnosis, treatment resistance, and clinical constructs of disease symptoms were evaluated as possible predictors of subsequent suicide-related events. Results: Ten baseline univariate predictors were identified. Historical predictors were diagnosis of schizoaffective disorder, history or current use at baseline of alcohol or substance abuse, cigarette smoking, number of lifetime suicide attempts, and the number of hospitalizations in the previous 36 months to prevent suicide. Predictive clinical features included greater baseline scores on the InterSePT scale for suicidal thinking, the Covi Anxiety Scale, the Calgary Depression Scale (CDS), and severity of Parkinsonism. Subsequent multivariate analysis revealed the number of hospitalizations in the previous 36 months, baseline CDS, severity of Parkinson's, history of substance abuse, and lifetime suicide attempts. Clozapine, in general, was more effective than olanzapine in decreasing the risk of suicidality, regardless of risk factors present. Conclusions: This is the first prospective analysis of predictors of suicide risk in a large schizophrenic and schizoaffective population judged to be at high risk for suicide. Assessment of these risk factors may aid clinicians in evaluating risk for suicidal behaviors so that appropriate interventions can be made. © 2003 Society of Biological Psychiatry.
Authors & Co-Authors
Potkin, Steven G.
United States, Irvine
University of California, Irvine
Alphs, Larry D.
Switzerland, Basel
Novartis International ag
Krishnan, K. Ranga Rama
United States, Durham
Duke University
Bitter, István
Unknown Affiliation
Carpiniello, Bernardo
Unknown Affiliation
Casey, Daniel E.
Unknown Affiliation
Daléry, Jean
Unknown Affiliation
Dell’Osso, Liliana
Unknown Affiliation
Emsley, Robin Alexander
Unknown Affiliation
Frangou, Sophia
Unknown Affiliation
Glick, Ira David
Unknown Affiliation
Jakovljević, Miro
Unknown Affiliation
Kerwin, Robert William
Unknown Affiliation
Larach, Verónica Walters
Unknown Affiliation
Llorca, Pierre Michel
Unknown Affiliation
Rapaport, Mark Hyman
Unknown Affiliation
Rouillon, Frederick
Unknown Affiliation
Simpson, George M.
Unknown Affiliation
Statistics
Citations: 90
Authors: 18
Affiliations: 5
Identifiers
Doi:
10.1016/S0006-3223(03)00178-1
ISSN:
00063223
Research Areas
Mental Health
Substance Abuse
Study Design
Randomised Control Trial
Cross Sectional Study
Cohort Study